Protective role of bortezomib in steatotic liver ischemia/reperfusion injury through abrogation of MMP activation and YKL-40 expression

Transplant Immunology

Volumn 30, Issue 2-3, 2014, Pages 93-98

  Tiriveedhi, Venkataswarup ^a,d   Upadhya, Gundumi A ^a   Busch, Rebecca A ^a   Gunter, Kristen L ^a   Dines, Jeff N ^b   Knolhoff, Bret L ^b   Jia, Jianluo ^a   Sarma, Nayan J ^a   Ramachandran, Sabarinathan ^a   Anderson, Christopher D ^c   Mohanakumar, Thallachallour ^a   Chapman, William C ^a  

^a WASHINGTON UNIVERSITY   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

^d TENNESSEE STATE UNIVERSITY   (United States)

Author keywords

Bortezomib; I R injury; Liver transplantation; Matrix metalloproteinases; YKL 40

Indexed keywords

BORTEZOMIB; FIBROBLAST GROWTH FACTOR 2; GAMMA INTERFERON; GELATINASE A; GELATINASE B; INTERLEUKIN 1BETA; MATRIX METALLOPROTEINASE; PROTEIN YKL 40; SCATTER FACTOR; SCLEROPROTEIN; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VASCULOTROPIN; ANTINEOPLASTIC AGENT; BORONIC ACID DERIVATIVE; CHI3L1 PROTEIN, RAT; GLYCOPROTEIN; MMP2 PROTEIN, RAT; MMP9 PROTEIN, RAT; PYRAZINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG EFFICACY; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME INHIBITION; FATTY LIVER; LIVER ISCHEMIA; LIVER PROTECTION; LIVER TRANSPLANTATION; NONHUMAN; OBESITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; REPERFUSION INJURY; UPREGULATION; ANIMAL; BIOSYNTHESIS; DRUG EFFECTS; GENE EXPRESSION REGULATION; METABOLISM; PATHOLOGY; ZUCKER RAT;

ANIMALS; ANTINEOPLASTIC AGENTS; BORONIC ACIDS; BORTEZOMIB; ENZYME ACTIVATION; EXTRACELLULAR MATRIX PROTEINS; FATTY LIVER; GENE EXPRESSION REGULATION; GLYCOPROTEINS; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; PYRAZINES; RATS; RATS, ZUCKER; REPERFUSION INJURY;

EID: 84896548322     PISSN: 09663274     EISSN: 18785492     Source Type: Journal    
DOI: 10.1016/j.trim.2013.12.003     Document Type: Article

References (40)

1. Clavien P.A., Petrowsky H., DeOliveira M.L., Graf R. Strategies for safer liver surgery and partial liver transplantation. N Engl J Med 2007, 356:1545-1559.
2. Trevisani F., Colantoni A., Caraceni P., Van Thiel D.H. The use of donor fatty liver for liver transplantation: a challenge or a quagmire?. J Hepatol 1996, 24:114-121.
3. Halon A., Patrzalek D., Rabczynski J. Hepatic steatosis in liver transplant donors: rare phenomenon or common feature of donor population?. Transplant Proc 2006, 38:193-195.
4. Wicklow B.A., Wittmeier K.D., MacIntosh A.C., Sellers E.A., Ryner L., Serrai H., et al. Metabolic consequences of hepatic steatosis in overweight and obese adolescents. Diabetes Care 2012, 35:905-910.
5. Todo S., Demetris A.J., Makowka L., Teperman L., Podesta L., Shaver T., et al. Primary nonfunction of hepatic allografts with preexisting fatty infiltration. Transplantation 1989, 47:903-905.
6. Selzner M., Clavien P.A. Fatty liver in liver transplantation and surgery. Semin Liver Dis 2001, 21:105-113.
7. Ploeg R.J., D'Alessandro A.M., Knechtle S.J., Stegall M.D., Pirsch J.D., Hoffmann R.M., et al. Risk factors for primary dysfunction after liver transplantation-a multivariate analysis. Transplantation 1993, 55:807-813.
8. Pevni D., Frolkis I., Schwartz D., Schwartz I., Chernichovski T., Kramer A., et al. New evidence for the role of TNF-alpha in liver ischaemic/reperfusion injury. Eur J Clin Invest 2008, 38:649-655.
9. Hato S., Urakami A., Yamano T., Uemura T., Ota T., Hirai R., et al. Attenuation of liver and lung injury after hepatic ischemia and reperfusion by a cytokine-suppressive agent, FR167653. Eur Surg Res 2001, 33:202-209.
10. Jaeschke H. Mechanisms of Liver Injury. II. Mechanisms of neutrophil-induced liver cell injury during hepatic ischemia-reperfusion and other acute inflammatory conditions. Am J Physiol Gastrointest Liver Physiol 2006, 290:G1083-G1088.
11. Muller-Quernheim J. MMPs are regulatory enzymes in pathways of inflammatory disorders, tissue injury, malignancies and remodelling of the lung. Eur Respir J 2011, 38:12-14.
12. Soccal P.M., Gasche Y., Pache J.C., Schneuwly O., Slosman D.O., Morel D.R., et al. Matrix metalloproteinases correlate with alveolar-capillary permeability alteration in lung ischemia-reperfusion injury. Transplantation 2000, 70:998-1005.
13. Cheung P.Y., Sawicki G., Wozniak M., Wang W., Radomski M.W., Schulz R. Matrix metalloproteinase-2 contributes to ischemia-reperfusion injury in the heart. Circulation 2000, 101:1833-1839.
14. Romanic A.M., White R.F., Arleth A.J., Ohlstein E.H., Barone F.C. Matrix metalloproteinase expression increases after cerebral focal ischemia in rats: inhibition of matrix metalloproteinase-9 reduces infarct size. Stroke 1998, 29:1020-1030.
15. Sarma N.J., Tiriveedhi V., Subramanian V., Shenoy S., Crippin J.S., Chapman W.C., et al. Hepatitis C virus mediated changes in miRNA-449a modulates inflammatory biomarker YKL40 through components of the NOTCH signaling pathway. PLoS One 2012, 7:e50826.
16. Johansen J.S., Christoffersen P., Moller S., Price P.A., Henriksen J.H., Garbarsch C., et al. Serum YKL-40 is increased in patients with hepatic fibrosis. J Hepatol 2000, 32:911-920.
17. Hottinger A.F., Iwamoto F.M., Karimi S., Riedel E., Dantis J., Park J., et al. YKL-40 and MMP-9 as serum markers for patients with primary central nervous system lymphoma. Ann Neurol 2011, 70:163-169.
18. Chen D., Frezza M., Schmitt S., Kanwar J., Dou Q.P. Bortezomib as the first proteasome inhibitor anticancer drug: current status and future perspectives. Curr Cancer Drug Targets 2011, 11:239-253.
19. Ramachandran S., Liaw J.M., Jia J., Glasgow S.C., Liu W., Csontos K., et al. Ischemia-reperfusion injury in rat steatotic liver is dependent on NFkappaB P65 activation. Transpl Immunol 2012, 26:201-206.
20. Argiles J.M. The obese Zucker rat: a choice for fat metabolism 1968-1988: twenty years of research on the insights of the Zucker mutation. Prog Lipid Res 1989, 28:53-66.
21. Kamada N., Calne R.Y. A surgical experience with five hundred thirty liver transplants in the rat. Surgery 1983, 93:64-69.
22. Woessner J.F. Quantification of matrix metalloproteinases in tissue samples. Methods Enzymol 1995, 248:510-528.
23. Campbell L.G., Ramachandran S., Liu W., Shipley J.M., Itohara S., Rogers J.G., et al. Different roles for matrix metalloproteinase-2 and matrix metalloproteinase-9 in the pathogenesis of cardiac allograft rejection. Am J Transplant 2005, 5:517-528.
24. Tiriveedhi V., Angaswamy N., Brand D., Weber J., Gelman A.G., Hachem R., et al. A shift in the collagen V antigenic epitope leads to T helper phenotype switch and immune response to self-antigen leading to chronic lung allograft rejection. Clin Exp Immunol 2012, 167:158-168.
25. Vandooren J., Geurts N., Martens E., Van den Steen P.E., Opdenakker G. Zymography methods for visualizing hydrolytic enzymes. Nat Methods 2013, 10:211-220.
26. Tiriveedhi V., Angaswamy N., Weber J., Mohanakumar T. Lipid raft facilitated ligation of K-alpha1-tubulin by specific antibodies on epithelial cells: Role in pathogenesis of chronic rejection following human lung transplantation. Biochem Biophys Res Commun 2010, 399:251-255.
27. Tiriveedhi V., Gelman A.E., Mohanakumar T. HIF-1alpha signaling by airway epithelial cell K-alpha1-tubulin: role in fibrosis and chronic rejection of human lung allografts. Cell Immunol 2012, 273:59-66.
28. Hamada T., Fondevila C., Busuttil R.W., Coito A.J. Metalloproteinase-9 deficiency protects against hepatic ischemia/reperfusion injury. Hepatology 2008, 47:186-198.
29. Page-McCaw A., Ewald A.J., Werb Z. Matrix metalloproteinases and the regulation of tissue remodelling. Nat Rev Mol Cell Biol 2007, 8:221-233.
30. Nagase H., Visse R., Murphy G. Structure and function of matrix metalloproteinases and TIMPs. Cardiovasc Res 2006, 69:562-573.
31. Pizano-Martinez O., Yanez-Sanchez I., Alatorre-Carranza P., Miranda-Diaz A., Ortiz-Lazareno P.C., Garcia-Iglesias T., et al. YKL-40 expression in CD14(+) liver cells in acute and chronic injury. World J Gastroenterol 2011, 17:3830-3835.
32. Hu J., Van den Steen P.E., Sang Q.X., Opdenakker G. Matrix metalloproteinase inhibitors as therapy for inflammatory and vascular diseases. Nat Rev Drug Discov 2007, 6:480-498.
33. Shirahane K., Yamaguchi K., Koga K., Watanabe M., Kuroki S., Tanaka M. Hepatic ischemia/reperfusion injury is prevented by a novel matrix metalloproteinase inhibitor, ONO-4817. Surgery 2006, 139:653-664.
34. Bradham C.A., Schemmer P., Stachlewitz R.F., Thurman R.G., Brenner D.A. Activation of nuclear factor-kappaB during orthotopic liver transplantation in rats is protective and does not require Kupffer cells. Liver Transpl Surg 1999, 5:282-293.
35. Yoshidome H., Kato A., Edwards M.J., Lentsch A.B. Interleukin-10 suppresses hepatic ischemia/reperfusion injury in mice: implications of a central role for nuclear factor kappaB. Hepatology 1999, 30:203-208.
36. Racanelli V., Rehermann B. The liver as an immunological organ. Hepatology 2006, 43:S54-S62.
37. Bode C., Bode J.C. Activation of the innate immune system and alcoholic liver disease: effects of ethanol per se or enhanced intestinal translocation of bacterial toxins induced by ethanol?. Alcohol Clin Exp Res 2005, 29:166S-171S.
38. Demetris A.J., Adeyi O., Bellamy C.O., Clouston A., Charlotte F., Czaja A., et al. Liver biopsy interpretation for causes of late liver allograft dysfunction. Hepatology 2006, 44:489-501.
39. Bigg H.F., Wait R., Rowan A.D., Cawston T.E. The mammalian chitinase-like lectin, YKL-40, binds specifically to type I collagen and modulates the rate of type I collagen fibril formation. J Biol Chem 2006, 281:21082-21095.
40. Mutlu G.M., Budinger G.R., Wu M., Lam A.P., Zirk A., Rivera S., et al. Proteasomal inhibition after injury prevents fibrosis by modulating TGF-beta(1) signalling. Thorax 2012, 67:139-146.